Organon & Co. (OGN)

NYSE: OGN · IEX Real-Time Price · USD
17.45
-0.83 (-4.54%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-4.54%
Market Cap 4.46B
Revenue (ttm) 6.26B
Net Income (ttm) 1.02B
Shares Out 255.64M
EPS (ttm) 3.99
PE Ratio 4.37
Forward PE 3.98
Dividend $1.12 (6.42%)
Ex-Dividend Date Feb 23, 2024
Volume 2,629,684
Open 18.19
Previous Close 18.28
Day's Range 17.33 - 18.24
52-Week Range 10.84 - 24.79
Beta 0.79
Analysts Buy
Price Target 22.50 (+28.94%)
Earnings Date May 2, 2024

About OGN

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple o... [Read more]

Sector Healthcare
Founded 1923
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN
Full Company Profile

Financial Performance

In 2023, Organon & Co.'s revenue was $6.26 billion, an increase of 1.44% compared to the previous year's $6.17 billion. Earnings were $1.02 billion, an increase of 11.56%.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OGN stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 28.94% from the latest price.

Price Target
$22.5
(28.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024.

5 days ago - Business Wire

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endp...

5 days ago - Business Wire

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary.

7 weeks ago - Business Wire

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023.

2 months ago - Business Wire

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release fourth quarter and full year 2023 financial results on February 15, 2024, and hold a webcast and conference call at 8:30 AM EST.

2 months ago - Business Wire

Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's regular dividend to remain primary capital allocation priority. Organon affirms 2023 guidance and provides 2024 outlook.

3 months ago - Business Wire

11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria

Investors have different approaches to stock dividends. Some have no interest in current income and would prefer companies to focus on growing their businesses, rather than distributing cash to shareh...

3 months ago - Market Watch

Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference, Tuesday January 9.

4 months ago - Business Wire

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

JERSEY CITY, N.J.--(BUSINESS WIRE) Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe.

Other symbols: LLY
4 months ago - Business Wire

Jenny Harrington's top dividend picks for 2024: OGN, NYCB, WHR, CWEN, OKE, CCI and STX

Jenny Harrington, Gilman Hill Asset Management CEO, discusses her top dividend picks for 2024.

Other symbols: CCICWENNYCBOKESTXWHR
4 months ago - CNBC Television

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief F...

5 months ago - Business Wire

Organon Reports Results for the Third Quarter Ended September 30, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the Third Quarter Ended September 30, 2023.

5 months ago - Business Wire

Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed

JERSEY CITY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Organon and Sempre Health launch partnership to motivate patients to refill prescriptions on time and improve adherence via supportive pricing progr...

5 months ago - Business Wire

Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release third quarter 2023 financial results on November 2, 2023, prior to the webcast and conference call scheduled for 8:30 a.m. EST.

6 months ago - Business Wire

Lululemon Athletica & Hubbell Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK , Oct. 13, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the opening of trading on...

Other symbols: ATVIHUBBLULUONTO
6 months ago - PRNewsWire

Organon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice.

7 months ago - Business Wire

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Bolsters Research & Development Expertise with Two Leadership Appointments.

7 months ago - Business Wire

Organon results beat estimates on demand for women heath products, biosimilars

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar drugs, sending the healthcare firm's shares up about...

8 months ago - Reuters

Organon Reports Results for the Second Quarter Ended June 30, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the Second Quarter Ended June 30, 2023.

8 months ago - Business Wire

Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023.

9 months ago - Business Wire

Final Trades: SLB, Organon, IQVIA & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: SLBDDOGIQV
9 months ago - CNBC Television

Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.

Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie' Inc.'s ABBV, +0.21% rh...

Other symbols: SSNLF
10 months ago - Market Watch

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while two other drugmakers entered t...

10 months ago - Reuters

Organon, Samsung Bioepis launch copycat for athritis drug Humira at 85% discount

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while another drugmaker entered the ...

Other symbols: ABBV
10 months ago - Reuters

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator.

10 months ago - Business Wire